Compare KEQU & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | ALDX |
|---|---|---|
| Founded | 1906 | 2004 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 89.3M |
| IPO Year | 1995 | 2014 |
| Metric | KEQU | ALDX |
|---|---|---|
| Price | $37.67 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 1.6K | ★ 660.9K |
| Earning Date | 03-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.27 | $1.07 |
| 52 Week High | $46.70 | $5.93 |
| Indicator | KEQU | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 38.51 |
| Support Level | $35.14 | $1.07 |
| Resistance Level | $37.97 | $1.60 |
| Average True Range (ATR) | 0.57 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 26.67 | 3.45 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.